Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2019

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

	Three Months Ended				Nine Months Ended
(In thousands)	March 31,				March 31,
Medical Indication	2019		2018		2019		2018
Antibiotic	$	3,789	$	3,801	$	12,066	$	10,701
Anti-Psychosis		20,616		9,336		45,540		47,127
Cardiovascular		22,783		18,514		70,233		39,955
Central Nervous System		9,424		8,395		22,808		24,137
Gallstone		3,041		3,828		7,744		15,674
Gastrointestinal		11,735		16,562		36,783		46,171
Glaucoma		659		875		1,719		5,706
Migraine		9,846		12,888		32,134		43,387
Muscle Relaxant		3,238		3,299		9,538		10,309
Pain Management		5,856		6,594		19,771		18,483
Respiratory		498		2,324		2,676		6,200
Thyroid Deficiency		55,210		69,975		197,564		185,983
Urinary		2,105		33		5,262		5,870
Other		16,062		12,376		37,230		38,178
Contract manufacturing revenue		7,932		5,586		20,498		15,771
Net sales	$	172,794	$	174,386	$	521,566	$	513,652

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2019		2018		2019		2018
Product 1	32	%	40	%	38	%	36	%
Product 2	11	%	4	%	8	%	8	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2019		2018		2019		2018
Customer A	31	%	—	%	16	%	—	%
Customer B	17	%	15	%	16	%	18	%
Customer C	16	%	32	%	21	%	27	%